Genetic retinal dystrophies (GRDs) are a heterogeneous group of disorders for which, until now, few therapeutic options have been available. In recent years, developments in translational research have led to numerous clinical studies and innovative therapeutic trials involving several approaches such as gene, pharmacological or cell therapy. Patients with DRGs and their families are keenly aware of these therapeutic advances, but often appear baffled by the information available in the various media, the different studies that may be proposed to them, and the procedures and acts that govern clinical research.